Ophiomics is clinical-stage Medtech company developing IVD devices (AI, genomics) for in oncology.
Ophiomics has raised $6.5M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
Ophiomics's investors include European Innovation Council, EISMEA, BlueCrow Capital.
Ophiomics is headquartered in Lisboa, Portugal.
Ophiomics is clinical-stage Medtech company developing IVD devices (AI, genomics) for in oncology.
Ophiomics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ophiomics — Funding & Investors." VCBacked, January 18, 2023, https://www.vcbacked.co/company/ophiomics. Accessed September 3, 2026.
VCBacked. (2023). Ophiomics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/ophiomics
{{cite web |title=Ophiomics — Funding & Investors |url=https://www.vcbacked.co/company/ophiomics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated